Sodium-Glucose Cotransporter 2 Inhibitors and Dementia Risk in Patients With Psychiatric Disorders

Is treatment with sodium-glucose cotransporter 2 (SGLT2) inhibitors associated with reduced risk of dementia and other neuropsychiatric outcomes among people with mood and psychotic disorders?In this cohort study of 112 725 patients using data from the US Department of Veterans Affairs health care system, exposure to an SGLT2 inhibitor was associated with a significantly lower risk of incident all-cause dementia and psychiatric emergency department visits.These findings support further research into the benefits of SGLT2 inhibitors in individuals with psychiatric disorders and a potential shared metabolic mechanism underlying psychiatric disorders and dementia.

Corresponding Author: Jaime Ramos-Cejudo, PhD, NYU Grossman School of Medicine, 145 E 32nd St, New York, NY (jaime.ramoscejudo@nyulangone.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.